Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy.
about
Aminoglycoside Prescribing and Surveillance in Cystic FibrosisNew developments in aminoglycoside therapy and ototoxicityMechanisms of aminoglycoside ototoxicity and targets of hair cell protection.Anti-apoptotic effect of dexamethasone in an ototoxicity modelGentamicin differentially alters cellular metabolism of cochlear hair cells as revealed by NAD(P)H fluorescence lifetime imaging.Assessment of nutrient supplement to reduce gentamicin-induced ototoxicity.The zebrafish merovingian mutant reveals a role for pH regulation in hair cell toxicity and function.Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention.Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis.New trends in aminoglycosides use.Drug delivery to the ear.d-Methionine reduces tobramycin-induced ototoxicity without antimicrobial interference in animal models.Pulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers.Extended-Interval Aminoglycoside Use in Cystic Fibrosis Exacerbation in Children and Young Adults: A Prospective Quality Improvement ProjectThe Incidence of Amikacin Ototoxicity in Multidrug-ResistantTuberculosis Patients.Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis.Sensorineural hearing loss in patients with cystic fibrosis.Autophagic flux, a possible mechanism for delayed gentamicin-induced ototoxicity.The role of routine hearing screening in children with cystic fibrosis on aminoglycosides: A systematic review.Changes in the inner ear structures in cystic fibrosis patients.The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis.Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patientsHearing loss and vestibular dysfunction among children with cancer after receiving aminoglycosides.No hearing loss after repeated courses of tobramycin in cystic fibrosis patients.Parenteral administration of tobramycin for pulmonary exacerbations in cystic fibrosis patients: toxicity, serum levels and efficacy.Prevalence of hearing and vestibular loss in cystic fibrosis patients exposed to aminoglycosides.Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: A study using extended high-frequency audiometry and distortion product otoacoustic emissions.Minimizing the toxicity of aminoglycosides in cystic fibrosis.
P2860
Q22306318-712A0442-FE06-417A-9FC0-F9F0DB963EB7Q24599985-3A1DCB53-5152-4F36-B24E-AF77255C9FC5Q28393038-25A0ECE2-C63C-4169-ACA8-FEA18C65C941Q30358806-29CBEF5A-B898-4043-A56C-A1F9C20339E4Q30390875-0440BFAB-E2A4-4590-89B0-3FF9261C67B4Q30410332-C4C8092D-A907-45C9-8308-29383A94B9C5Q30434681-16197C2F-166D-4089-8239-A8CE26B06391Q30447637-EAE366B6-98E7-4926-A4B6-004928C3AAA7Q30479961-61DA41EC-3CF8-4894-A810-D6CEE9213820Q33951177-C832F1A0-635F-4479-8FBB-3AFDE25E6269Q34549540-E0589396-C525-4B6B-A7F3-41B8B2EC86EBQ36446781-691A7821-53A6-4A47-BE68-12D80D3264AFQ36980425-1A40368C-9A75-4EB9-B81A-51B9164AFE99Q36997685-28D8A1CE-D2B6-4D39-B21A-083826F960F6Q37268122-F0D5B3F7-292C-407C-8E9F-1153CBEFFE05Q37358664-538EC10A-1732-4E89-BEB0-C3B722606B00Q37533266-2145CED5-E8D0-4B81-9276-F2A6B5CB7002Q37618066-865ABC87-35E4-4482-83A9-99B4C87CDA63Q38543712-BA5B6D65-32BA-4BC2-9DF9-1DFF1C90E4BFQ39066887-AC502B03-A8FA-4367-B4A5-5A2E1CD5D5EEQ40317145-E8DB84A1-48CF-4878-9DB7-1EECA3848EA0Q41474199-F2129A9C-64B8-4435-8F5E-F6D4C1D8EB58Q45257429-0D91AB5D-430C-453A-AD6D-B1F3A3AFF70DQ45991071-745E6670-546E-486F-AC6A-7FD06059EF51Q46083235-29462986-25A9-418A-B940-3BF6F212B50BQ48358705-EF6C4897-86E2-463E-9CEB-5EB7F33F91BDQ50435277-330F0C19-FC49-4CA7-AAFD-EE8423C2DF23Q50437553-94E5B2C6-D3D9-4D99-8550-42F7E68C39C9
P2860
Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Occurrence and risk of cochleo ...... h-dose aminoglycoside therapy.
@ast
Occurrence and risk of cochleo ...... h-dose aminoglycoside therapy.
@en
type
label
Occurrence and risk of cochleo ...... h-dose aminoglycoside therapy.
@ast
Occurrence and risk of cochleo ...... h-dose aminoglycoside therapy.
@en
prefLabel
Occurrence and risk of cochleo ...... h-dose aminoglycoside therapy.
@ast
Occurrence and risk of cochleo ...... h-dose aminoglycoside therapy.
@en
P2093
P2860
P1476
Occurrence and risk of cochleo ...... gh-dose aminoglycoside therapy
@en
P2093
D E Stableforth
D W Morgan
M Mulheran
P2860
P304
P356
10.1128/AAC.45.9.2502-2509.2001
P407
P50
P577
2001-09-01T00:00:00Z